Is It Safe to Seek Screening and Treatment for Breast Cancer During the Pandemic?

Managing breast cancer screening and treatment can be worrisome in the best of times. During the COVID-19 pandemic, you may be even more uncertain. Elisa Port, MD, Director of the Dubin Breast Center of The Tisch Cancer Institute at Mount Sinai, answers some of your questions.

I’m due for my annual mammogram but I’m scared of getting COVID-19. Should I delay until there’s a vaccine?

At the height of the pandemic in New York City, we were not recommending women come in for screenings. We asked women seeking elective care and routine follow-up appointments to wait. But the number of cases in New York has dropped dramatically, and we have instituted stringent protocols making our hospitals and medical facilities extremely safe. We hope everyone will get back on track with routine screening tests, including mammograms.

I feel a lump in my breast. Should I get it checked out or wait and hope it goes away?

Any woman who thinks she might have a lump in her breast should get it checked out. While many lumps are benign, women of all ages and backgrounds can get breast cancer. It’s important not to dismiss your concern and assume a lump will go away. I recommend that you make an appointment with your primary care physician to receive a full evaluation. Your doctor might perform a physical exam and order imaging tests such as mammograms or ultrasounds or even a biopsy.     

I successfully completed my breast cancer treatment. Am I immunocompromised and at increased risk of developing COVID-19?  

A history of breast cancer does not increase your risk of contracting COVID-19 and neither does receiving cancer treatment—including hormonal therapies and other medications. However, women who are actively receiving chemotherapy and who are immunocompromised, may be at higher risk. The signs of COVID-19 are generally the same for breast cancer patient as they for anyone else. At Mount Sinai, we screen everyone coming into our facilities for issues such as fever, cough, and travel from an area with a high positivity rate (“red zone”).

I’m feeling stressed because of the pandemic. Do you have any suggestions on how to cope?

Stress management is very personal. Coping mechanisms, too, are very personal. The most important thing is to make sure that you don’t spiral into negative behaviors, such as overeating or drinking too much. Try to find healthy outlets for your stress. That can include physical activities like walking your dog or exercising; social activities such as spending time with friends and family; or doing things that bring you joy, like reading, listening to music, or playing a musical instrument. For more on how to cope during the COVID-19 pandemic, read this article on resiliency featuring Rachel Yehuda, PhD, Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai.

Do you have any other thoughts about breast health?

Remember that breast cancer is an extremely treatable and curable cancer—and early detection and diagnosis are key to successful treatment. The best way to find a cancer early is by getting regular screenings. Starting treatment when a cancer is in the early stages is most effective as it can also mean using less aggressive treatment.

What Patients with Breast or Gynecologic Cancer Need to Know About COVID-19

People with breast or gynecologic cancer may be at increased risk for COVID-19. This may be because of the cancer itself or due to cancer treatment weakening the immune system and making them more susceptible, or because they have more encounters with the healthcare system. Elisa R. Port, MD, Director of the Dubin Breast Center and Chief of Breast Surgery for The Mount Sinai Hospital, and Stephanie V. Blank, MD, Director of Gynecologic Oncology for the Mount Sinai Health Stem and Director of Women’s Health at the Blavatnik Family- Chelsea Medical Center at Mount Sinai, discuss what you need to know about breast and gynecologic cancer and COVID-19.

Is it safe to go to my oncology appointment?

Dr. Blank: Whether you should keep your appointment depends on the purpose of the visit. If you are having a routine mammogram or an annual check-up, you may be able to reschedule your appointment for later. It is a matter of weighing the risks and benefits of going to the appointment with possibly exposing yourself to the virus. Talk with your doctor to see what he or she recommends.

The Centers for Disease Control and Prevention has recommended that people do not go to the doctor for non-essential appointments. They want to protect you from people who might have or be carrying COVID-19. While we do our best to keep our offices as safe as possible, we cannot guarantee that someone who is asymptomatic has not been in the waiting or exam room. That said, we do limit the number of people entering the facility, so waiting rooms are empty and very few patients are on site.

The other question is how to get to the appointment. I would try to avoid public transportation if possible. If you do not have another option, I would encourage you to wear a face mask, carry hand sanitizer, wash your hands frequently, and be careful about what you touch. You would also want to distance yourself from people. Luckily, public transportation is a lot less crowded than usual, so it should be easier than usual to keep your distance from others.

Why did my doctor cancel my appointment?

Dr. Blank: If your doctor cancelled your appointment, chances are your doctor considered the reason for the appointment and the risk of exposure to COVID-19 and determined that the benefits of the appointment did not outweigh the risks. But, if you are concerned, contact your doctor and ask. The first question is whether the appointment was cancelled altogether or delayed for a period.

If you really want to talk to your doctor sooner rather than later, telehealth is an option in most health care systems. This allows you to discuss your concerns with your doctor without physically being in the same space. If your doctor does not have telehealth capabilities, try setting up a telephone conversation.

I think I might have COVID-19. What do I do?

Dr. Port: If you develop symptoms that suggest COVID-19, such as cough, fever or difficulty breathing, you should call your doctor. Discuss these symptoms with your doctor and get his or her advice. Availability of COVID-19 testing varies across the county, so your ability to be tested will depend on where you are. In addition to talking to your doctor, you should isolate yourself in your home to avoid possibly spreading the virus. Keep away from others in your home to protect them as well. Your doctor should be able to provide additional advice.

I’m Concerned I May Have Cancer. Can I See A Doctor During the COVID-19 Pandemic?

The business world may be on pause due to the COVID-19 pandemic, but that does not mean medical conditions have taken a reprieve. If you are worried that you might have breast or gynecologic cancer, you need expert advice. Elisa R. Port, MD, Director of the Dubin Breast Center and Chief of Breast Surgery for the Mount Sinai Hospital, and Stephanie V. Blank, MD, Director of Gynecologic Oncology for the Mount Sinai Health System and Director of Women’s Health at the Blavatnik Family- Chelsea Medical Center at Mount Sinai, discuss what you need to know about breast and gynecologic cancer and COVID-19.

I have symptoms that make me worried I might have cancer. Should I see a doctor or wait until the pandemic subsides?

Dr. Port: If you feel a lump in your breast, have unexplained weight loss, unusual bleeding or bloating, changes to the color or texture of the skin on the outside of your genitals, or other concerning signs, you should definitely get checked out. Do not delay seeing medical attention due to the pandemic.

Most doctors, including those in the Mount Sinai Health System, are open for business to evaluate potential patients. We encourage patients to reschedule non-essential visits such as routine annual mammograms and check-ins. This helps us keep the office (and waiting room) mostly empty so we can see new or potential patients while maintaining and allowing you to maintain social distancing. When you come into the office, we take you immediately into a private exam room to limit the risk of exposure. We continue to perform imaging tests, biopsies, and other key diagnostic examinations.

If I am diagnosed with breast cancer, will I receive treatment now, or will I need to wait until after COVID-19 has subsided?

Dr. Port: The short answer is: It depends.

It’s important to remember there are dozens of types and subtypes of breast cancer. There are also a variety of treatment options; there’s no one-size-fits-all approach. We can safely delay treatment for some types of very early breast cancers. Others respond to medication that can prevent growth of the cancer until the threat of COVID-19 has decreased and we can more safely proceed with treatment. But the first step is to get an accurate diagnosis.

Fortunately, there are very few emergency situations where you need surgery or treatment within a day or two to prevent a bad or worse outcome. In most cases, we have the luxury of being able to delay treatment without affecting your overall prognosis and survival rate. It is all about balancing the risks and benefits in your individual case.

Some cancers grow very slowly, so we can safely delay care for one to three months. Others may respond to a medication, such as an anti-hormonal drug, that can allow us to hold off on care for a while. If you have a more aggressive type of cancer, we may decide to do surgery or start chemotherapy.

Of course, receiving these treatments in the setting of a pandemic carries certain risks of immunosuppression and we don’t take those risks lightly. Even just coming to the hospital carries some risk. So, we will talk with you about the risks and benefits of each care option and decide together on the most appropriate approach for your individual situation.

Is it safe to have chemotherapy now?

Dr. Blank: Again, there is no blanket answer to this question. You and your doctor need to consider your individual situation. First, it depends on the purpose of chemotherapy. Is it going to cure you? If so, you may not want to interrupt it. If it is controlling your symptoms, that may be a different conversation. You may be able to increase the time between treatments, or there may be another way to help with your symptoms.

At Mount Sinai, we test women for COVID-19 before we start chemotherapy because we know that women who have the virus and are in treatment may get significantly sicker than others. We also take measures to boost patients’ blood counts during this time to help patients fight the disease should they contract it.

Is it safe to have surgery now?

Dr. Blank: Here, too, the answer is not simple. In general, we are trying to delay all the surgeries that we believe can be safely postponed. The reason is that you really don’t want to be in a hospital right now. There are a lot of COVID-19-positive patients there and you may well be exposed to the virus. We look at the risks and benefits and discuss the issues with our patients. We are not delaying the procedures permanently, just until we have a safe environment for our patients so we can perform procedures again. This is not unusual. We often delay surgery when it is safe to do so. Sometimes a patient wants to delay so she can attend a daughter’s wedding or a grandson’s graduation.

Sometimes we can change our treatment approach to avoid or delay surgery. We can change the order of treatment. For instance, if someone was recently diagnosed with ovarian cancer, we may start with chemotherapy instead of surgery. Then we can perform the surgery later, when it is safer. We know that’s safe cancer-wise; we have a lot of data that show this.  Sometimes we can use a different treatment approach. For example, we can treat certain endometrial cancers with hormones. Talk with your cancer doctors; they can tell you what the options are in your individual situation.

What do Cancer Patients Need to Know about COVID-19?

COVID-19 is a concern for everyone. But cancer patients are among those at highest risk of contracting this virus–or developing a bad case of it. This is because most cancer patients have immune systems that have been weakened by cancer and its treatments. Cardinale B. Smith, MD, PhD, Chief Quality Officer for Cancer, shares information cancer patients need to know about COVID-19.

How can patients and caregivers protect themselves from COVID-19?

The most important thing that patients and caregivers can do is practice really great hand hygiene. Make sure to wash your hands for at least 20 seconds. You’ve probably heard about singing the Happy Birthday song twice; that is usually the right amount of time to soap and rinse your hands. If you are using hand sanitizer, make sure to pick one that is more than 60 percent alcohol.

Someone with cancer should limit contact with anyone who might be sick. Avoid large crowds and practice social distancing. The Centers for Disease Control and Prevention defines social distancing, in terms of COVID-19, as keeping six feet away from others. That means avoiding subways, buses, and other mass transit, and staying at home as much as possible. You can turn events that often involve large groups into virtual activities. Instead of going to the gym, for instance, you could watch a YouTube video and exercise along with it.

Which cancer patients are at greatest risk?

All cancer patients are at increased risk but patients at greatest risk are those who have recently had a bone marrow transplant or have blood cancers such as leukemia, lymphoma, and myeloma. Patients with these conditions tend to receive medications with a high concentration of immunosuppressants. If you finished treatment a while ago, you are probably not at increased risk.

What should I do if I have symptoms of COVID-19?

Cancer patients with symptoms that suggest COVID-19, such as coughing and high fever, should call their oncology team for expert guidance. Your oncologist is most likely to know if your symptoms suggest COVID-19 or if they are likely to be the flu, another respiratory infection, or if the symptoms are in line with your cancer diagnosis. Your cancer team can tell you if you need to come into the office to be checked.

What if I am feeling anxious?

Anxiety around COVID-19 is really high. Remember that for the vast majority of people who contract COVID-19, the virus is not fatal. Try not to let your fears get the best of you. Keep calm and practice the basic tips we talked about. That is your best bet, in terms of prevention.

What You Should Know About Gynecologic Cancers

In September 2019, we met with Stephanie Blank, MD, Blavatnik Family Women’s Health Research Institute faculty member, to discuss gynecologic cancers in recognition of Gynecologic Cancer Awareness Month. Dr. Blank is a Professor of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai, as well as Director of Gynecologic Oncology for the Mount Sinai Health System. She practices at the Mount Sinai Blavatnik Family – Chelsea Medical Center, where she leads the Women’s Cancer Program. Dr. Blank has also been recently elected as the President of the Society of Gynecologic Oncology.

Dr. Blank primarily focuses on caring for women with ovarian, uterine, and cervical cancer and those who are at an increased genetic risk for these gynecologic cancers. Her current research focuses on the significance of genetics on cancer risk management, including BRCA variants, as well as making genetic testing accessible to those at risk.

In our video Q&A, Dr. Blank discussed screening recommendations and methods for gynecologic cancers; risk factors and symptoms of gynecologic cancers; her role as a gynecologic oncologist; and what she first tells her patients when they are diagnosed with a gynecologic cancer. Dr. Blank assures her patients that “the treatment for all these diseases is really moving forward” and “we can help a lot of women.”

For Gynecologic Cancer Awareness Month, Mount Sinai held a health fair at the Guggenheim Pavilion to educate staff and patients on how to understand symptoms and risk factors in order to make proper health care decisions. Representatives from Woman to Woman, a network at Mount Sinai of volunteer survivors of gynecologic cancers who provide one-on-one support and education to women currently in treatment, attended. Guidance from women who understand the grueling situation a woman with a gynecologic cancer is in could help emotionally support the patient in conjunction with her treatment.

Thank you to the women of Woman to Woman and Dr. Blank for your exceptional work!

Examining the Effects of Immunotherapy on Cancer

From left: Thomas Marron, MD, PhD; Adeeb Rahman, PhD, Associate Professor, Genetics and Genomic Sciences; and Miriam Merad, MD, PhD

Using a collection of sophisticated single-cell technologies, scientists at the Mount Sinai Health System have launched an early-stage clinical trial that examines the effects of immunotherapy on hepatocellular carcinoma, non-small-cell lung cancer, and head and neck squamous cell carcinoma.

Four to six weeks before a tumor is resected, the researchers administer a neoadjuvant immunotherapy, cemiplimab, and study its effects. As soon as the tumor is removed, they continue to analyze the fresh tissue for a month or more to observe mechanisms of resistance and response. The Phase 1 trial is sponsored by Regeneron Pharmaceuticals, Inc.

“With the technologies available to us at The Tisch Cancer Institute and Mount Sinai’s Human Immune Monitoring Center, we are able to investigate at an unprecedented depth how these immune therapies are changing the microenvironment within the tumor,” says Thomas Marron, MD, PhD, Assistant Professor of Medicine (Hematology and Medical Oncology), Icahn School of Medicine at Mount Sinai, and Principal Investigator of the study. “This trial enables us to analyze fresh tissue immediately after resection—instead of the preserved tissue typically obtained in trials—to observe the dynamic changes that occurred.”

The study is enrolling multiple small cohorts of 21 patients. One goal is to determine which cancer patients will benefit from cemiplimab, and, more specifically, how cemiplimab can be more effective by combining it with chemotherapy and/or other novel immunotherapies. Cemiplimab was previously studied at Mount Sinai in liver and lung cancer patients and has been approved by the U.S. Food and Drug Administration for patients with metastatic cutaneous squamous cell carcinoma. The compound works by inhibiting the interaction between PD-L1, a protein on the surface of tumor cells, and PD-1, the protein on the surface of T cells, and restoring the immune system’s ability to recognize and kill cancer cells.

Another goal of the study is to identify biomarkers in human tissue and blood that will be able to predict who will respond to immunotherapy, since so many patients do not respond to anti-PD-1 therapy. “We really need to find the ideal patients to treat so we don’t unnecessarily expose those who won’t respond to the toxicity of immune therapies,” says Dr. Marron, who is also Assistant Director of Early Phase and Immunotherapy Clinical Trials at Mount Sinai. “There’s also a financial issue at stake for patients and society in general in using expensive drugs that are not improving outcomes.”

Dr. Marron and his team are using several powerful new technologies to help them with their work. These include immune mapping and monitoring technologies such as mass cytometry (CyTOF), a flow-cytometry-like technology that allows them to see up to 50 proteins on each cell so they can identify the cell type and classify the maturation and activation status of the cell, along with some of the regulatory “on/off” checkpoints.

CITE-Seq (Cellular Indexing of Transcriptomes and Epitopes by Sequencing) is another platform that provides an even higher resolution view of each individual cell within the tumor. This technology combines the capabilities of CyTOF and single-cell RNA sequencing to characterize both the RNA and protein in each cell.

A third technology is known as Multiple Ion Beam Imaging (MIBI), a unique form of immunohistochemistry that allows scientists, for the first time, to unravel the spatial architecture of tumors in order to better understand the mechanisms through which the immune system is infiltrating the tumor and is being hijacked by the tumor.

“For 10 years, we’ve been building the Human Immune Monitoring Center into one of the leading platforms in the world for investigating the role of the immune system in human disease, and using that knowledge to design novel, immune-based therapies,” says Miriam Merad, MD, PhD, Director of the Center, and Professor of Oncological Sciences, and Medicine, Icahn School of Medicine at Mount Sinai.

Drawing on a highly specialized team of clinicians, immunologists, mathematicians, physicists, and surgeons, the Human Immune Monitoring Center is currently involved in more than 45 federal- and foundation-funded research programs in fields such as cancer, autoimmune disease, inflammatory bowel disease, allergies, and neurodegenerative disease.